Key Highlights:
- RPG Life Sciences has partnered with Archerchem Healthcare to launch Naprosyn ES, India’s first Naproxen and Esomeprazole fixed-dose combination. Co-developed by Archerchem and its development partner, the product combines anti-inflammatory efficacy with gastroprotection. Under the agreement, RPG Life Sciences will exclusively market and distribute Naprosyn ES across India, while Archerchem will serve as the exclusive supplier.
- Naprosyn ES is designed for patients requiring long-term NSAID therapy, particularly those at risk of gastrointestinal complications. The differentiated formulation aims to improve medication adherence while enabling safer long-term pain management, especially for elderly and gastro-sensitive patients. RPG highlighted that the launch reflects its patient-centric, R&D-driven strategy, while Archerchem emphasized its expertise in developing complex differentiated formulations.
- RPG Life Sciences plans to leverage the strong legacy of the Naprosyn brand, its extensive physician network, including super-specialists, and its pan-India distribution infrastructure to drive adoption. The launch strengthens the company’s differentiated portfolio in chronic therapies, with Naprosyn ES now available across India.
Implications:
RPG Life Sciences is launching India’s first fixed-dose Naproxen + Esomeprazole tablet, Naprosyn ES, to enable safer long-term NSAID use by adding gastroprotection alongside anti-inflammatory effect.
The product is co-developed by Archerchem, which will supply it, while RPG will exclusively market and distribute it across India using the strong Naprosyn legacy, a large physician network, and pan-India distribution, aiming to improve adherence and reduce GI complications in elderly and gastro-sensitive patients on chronic pain therapy.
Source: RPG Life Sciences
